Detalles de la búsqueda
1.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37789669
2.
mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response.
J Gastroenterol Hepatol
; 39(6): 1164-1171, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38403468
3.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37552968
4.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36455517
5.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37307798
6.
Metabolic dysfunction-associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis.
Hepatol Res
; 2023 Nov 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38015179
7.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res
; 53(10): 1031-1042, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37306040
8.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol
; 38(8): 1389-1397, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37231943
9.
Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Hepatol Res
; 51(8): 860-869, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34046970
10.
Cannabinoid receptor 1 knockout alleviates hepatic steatosis by downregulating perilipin 2.
Lab Invest
; 100(3): 454-465, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31570772
11.
Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules.
Int J Mol Sci
; 21(1)2019 Dec 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-31888083
12.
Compliance and problems with the surveillance program for HCC diagnosis.
Nihon Shokakibyo Gakkai Zasshi
; 114(7): 1255-1263, 2017.
Artículo
en Japonés
| MEDLINE | ID: mdl-28679981
13.
Renal shear wave velocity by acoustic radiation force impulse did not reflect advanced renal impairment.
Nephrology (Carlton)
; 21(12): 1056-1062, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26667380
14.
Clinical usefulness of the ablative margin assessed by magnetic resonance imaging with Gd-EOB-DTPA for radiofrequency ablation of hepatocellular carcinoma.
J Hepatol
; 63(6): 1360-7, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26232269
15.
Usefulness of contrast-enhanced ultrasound with Sonazoid for evaluating liver abscess in comparison with conventional B-mode ultrasound.
Hepatol Res
; 45(3): 337-42, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24773617
16.
Therapeutic effects of the direct renin inhibitor, aliskiren, on non-alcoholic steatohepatitis in fatty liver Shionogi ob/ob male mice.
Hepatol Res
; 44(8): 888-896, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23777387
17.
VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response.
J Med Ultrason (2001)
; 51(2): 293-300, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38147196
18.
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
Cancer Rep (Hoboken)
; 7(4): e2042, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38577725
19.
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Aliment Pharmacol Ther
; 2024 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38716823
20.
Right diaphragmatic defect in hepatic hydrothorax exposed by contrast-enhanced ultrasonography after radiofrequency ablation.
Hepatology
; 56(2): 784-5, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22618966